Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?

This article was originally published in Start Up

Executive Summary

Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.

Advertisement

Related Content

Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant
Good News, Bad News On Medication Adherence: Problem Understood, Now How To Fix Human Behavior?
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
When Interests Align: Medication Adherence

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel